Alzamend Neuro (Alzamend Neuro) EBIT per Share : $-1.87 (TTM As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro EBIT per Share?

Alzamend Neuro's EBIT per Share for the three months ended in Jan. 2024 was $-0.38. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.87.

During the past 3 years, the average EBIT per Share Growth Rate was -45.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Alzamend Neuro's EBIT per Share or its related term are showing as below:

ALZN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.7 Med: -40.25 Max: -34.8
Current: -45.7

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Alzamend Neuro was -34.80% per year. The lowest was -45.70% per year. And the median was -40.25% per year.

ALZN's 3-Year EBIT Growth Rate is ranked worse than
88.51% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs ALZN: -45.70

Alzamend Neuro's EBIT for the three months ended in Jan. 2024 was $-2.66 Mil.

Alzamend Neuro EBIT per Share Historical Data

The historical data trend for Alzamend Neuro's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro EBIT per Share Chart

Alzamend Neuro Annual Data

Trend

Apr19

Apr20

Apr21

Apr22

Apr23

EBIT per Share

-0.85

-0.74

-0.86

-2.07

-2.29

Alzamend Neuro Quarterly Data
	Apr19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT per Share	Get a 7-Day Free Trial													-0.83	-0.51	-0.54	-0.44	-0.38

Alzamend Neuro EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Alzamend Neuro's EBIT per Share for the fiscal year that ended in Apr. 2023 is calculated as

	EBIT per Share		(A: Apr. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-14.87	/	6.501
=	-2.29

Alzamend Neuro's EBIT per Share for the quarter that ended in Jan. 2024 is calculated as

	EBIT per Share		(Q: Jan. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.66	/	7.054
=	-0.38

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.87

Alzamend Neuro (NAS:ALZN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Alzamend Neuro EBIT per Share Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro (Alzamend Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326

Website

https://www.alzamend.com

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Executives

Ault Milton C Iii	10 percent owner	11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff	officer: Chief Operating Officer	201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman	director, officer: Chief Executive Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath	director	28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson	director	10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
William B. Horne	director	C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Henry Carl Nisser	director, officer: Exec VP and General Counsel	100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun	officer: SVP of Finance	3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram	director	15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien	officer: Chief Financial Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo	director	2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404